SCHEMBL30301697

SCHEMBL30301697

CC(C)(C)OC(=O)N1CCN(c2ccc(C(F)(F)F)cc2[N+](=O)[O-])CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.61
ALDH1A1 P00352 4/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
CYP2C9 P11712 3/20 0.59
CYP2C19 P33261 3/20 0.59
CYP2D6 P10635 2/20 0.59
CYP3A4 P08684 2/20 0.59
CYP1A2 P05177 1/20 0.59
GAA P10253 2/20 0.59
HTT P42858 2/20 0.59
NPSR1 Q6W5P4 2/20 0.58
ALOX12 P18054 2/20 0.58
MAPK1 P28482 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
LMNA P02545 5/20 0.56
CCR6 P51684 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PHGDH O43175 3/20 0.55
TDP1 Q9NUW8 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3730926 1.00 MAPT (0.61) MAPTALDH1A1MEN1KMT2ACYP2C9
SCHEMBL30301712 0.96 MAPT (0.65) MAPTALDH1A1MEN1KMT2ACYP2C9
SCHEMBL6629173 0.96 MAPT (0.65) MAPTALDH1A1MEN1KMT2ACYP2C9
SCHEMBL20495490 0.91 MAPT (0.56) MAPTALDH1A1MEN1KMT2ACYP2C9
SCHEMBL107879 0.90 MAPT (0.53) MAPTALDH1A1MEN1KMT2ACYP2C9
SCHEMBL15801197 0.86 MAPT (0.58) MAPTALDH1A1MEN1KMT2ACYP2C9
SCHEMBL13156273 0.86 MAPT (0.75) MAPTALDH1A1MEN1KMT2ACYP2C9
SCHEMBL28322333 0.86 MAPT (0.69) MAPTALDH1A1MEN1KMT2ACYP2C9
SCHEMBL4434853 0.85 MAPT (0.60) MAPTALDH1A1KMT2ACYP2C9CYP2C19
SCHEMBL15911569 0.84 MAPT (0.67) MAPTALDH1A1MEN1KMT2ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4182311-B1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES EXONATE LTD (GB) 2025-06-04 EP disclosed
US-20240300929-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES EXONATE LTD (GB) 2024-09-12 US disclosed
US-12024504-B2 1-methyl-1H-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases EXONATE LIMITED (GB) 2024-07-02 US disclosed
US-20220411412-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES EXONATE LIMITED (GB) 2022-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411412-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES VEGFA, FLT4, FLT1 MAPT 3137/4885ALDH1A1 1874/4885MEN1 3897/4885
US-20240300929-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES VEGFA, FLT4, FLT1 MAPT 3137/4885ALDH1A1 1874/4885MEN1 3897/4885
US-12024504-B2 1-methyl-1H-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases VEGFA, FLT4, FLT1 MAPT 3137/4885ALDH1A1 1874/4885MEN1 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.